Anthony Caggiano
Known title: Chief Medical OfficerCIK: 0001892981
Anthony Caggiano's purchase track record
Anthony Caggiano has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 4/16/2026 | CGTX | $11K | -15.3% | -34.0% | +10.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CGTX | ▲ Buy | Open Market | 10,000 | $11K | 4/16/2026 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 4,680 | $5K | 2/15/2026 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 26,919 | $28K | 2/4/2026 | View on chart |
| CGTX | ▲ Buy | Grant | 400,000 | $0 | 2/3/2026 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 11,488 | $13K | 2/3/2026 | View on chart |
| CGTX | ▲ Buy | Grant | 65,000 | $0 | 12/18/2025 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 20,280 | $30K | 12/18/2025 | View on chart |
| CGTX | ▲ Buy | Grant | 65,000 | $0 | 7/29/2025 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 20,281 | $14K | 7/29/2025 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 5,296 | $3K | 2/15/2025 | View on chart |
| CGTX | ▲ Buy | Grant | 295,000 | $0 | 2/4/2025 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 12,779 | $9K | 2/3/2025 | View on chart |
| CGTX | ▲ Buy | Grant | 60,000 | $0 | 2/15/2024 | View on chart |
| CGTX | ▼ Sell | Tax Withholding | 12,777 | $29K | 2/3/2024 | View on chart |
| CGTX | ▲ Buy | Grant | 94,406 | $0 | 2/3/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20
Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.
Cognition Therapeutics Sets FDA Type C Meeting for Oct. 20. Cognition Therapeutics announced it will hold a Type C meeting with the FDA on October 20 regarding the planned trial of zervimesine. This regulatory step is a key milestone for the drug's development path. The company's stock currently trades within a wide 52-week range, reflecting the uncertainty typical of clinical-stage biotech firms.